NCT04087174 2022-07-13A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerAstraZenecaPhase 1 Completed27 enrolled